The FDA has granted accelerated approval to Avmapki (avutometinib) plus Fakzynja (defactinib) for the treatment of KRAS-mutated, recurrent low-grade serous ovarian cancer.

The Trump administration has terminated National Institutes of Health (NIH) grants totaling more than $1.8 billion, and the National Cancer Institute (NCI) is among the top 5 institutes with the most ...

The HHS and FDA are encouraging stakeholders to submit their ideas for deregulatory actions in the next 60 days.

Researchers found a significant tradeoff between harms and benefits for patients who received an ICI plus chemotherapy in the first-line setting.

Penpulimab-kcqx, a humanized immunoglobulin G1 monoclonal antibody, blocks the interaction between the programmed death 1 receptor on T-cells and programmed death ligand 1 and 2 on tumor cells.

Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.

Our trial provides proof of concept that cytokine-armored CAR T-cell treatment is feasible and may enhance antitumor activity without additional toxic effects,” researchers reported.

B-cell maturation antigen (BCMA)-directed bispecific antibodies have tolerable safety profiles in frail patients with relapsed/refractory multiple myeloma (MM), according to a real-world study ...

The researchers also observed significant increases in mortality for at least 1 age group for the following cancers: testicular cancer, uterine cancer, female breast cancer, bone and joint cancer, ...

The president has signed an executive order stating that the US will institute a “most-favored-nation” policy, whereby the US will pay the same price for a drug as the nation that pays the lowest ...

New research suggests that outpatients with cancer are more likely than other outpatients to have antimicrobial-resistant bacterial pathogens.

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.